Joël Guigay, Keun-Wook Lee, Manish R Patel, Amaury Daste, Deborah J Wong, Sanjay Goel, Michael S Gordon, Martin Gutierrez, Ani Balmanoukian, Christophe Le Tourneau, Alain Mita, Damien Vansteene, Ulrich Keilholz, Patrick Schöffski, Hans Juergen Grote, Dongli Zhou, Marcis Bajars, Nicolas Penel
BACKGROUND: Recurrent and/or metastatic (R/M) disease develops in approximately 65% of patients with squamous cell carcinoma of the head and neck (SCCHN) and is associated with a poor prognosis. Immune checkpoint inhibitors have proven effective in multiple tumor types, including R/M SCCHN. We report the efficacy and safety of avelumab (antiprogrammed death ligand 1 antibody) in an expansion cohort of patients with platinum-refractory/ineligible R/M SCCHN enrolled in the phase I JAVELIN Solid Tumor trial (NCT01772004)...
October 2021: Journal for Immunotherapy of Cancer